# Cap Table Management & Series B Readiness Analysis ## 1. Cap Table Audit & Baseline Validation ### Current Ownership Structure Your cap table shows **11.5M fully diluted shares** with the following breakdown: **Common Stock (8M authorized, 6M issued):** - Founder A: 3.2M shares (2.56M vested, 640K unvested) - Founder B: 2.4M shares (1.92M vested, 480K unvested) - Early employees: 400K shares (240K-320K vested range) - CFO exercised: 50K shares (now common, no longer options) **Series A Preferred (2M issued):** - Lead VC: 1.2M shares ($3M invested) - Angels: 800K shares ($2M invested) - Economic rights: 1x participating preferred with full ratchet protection via broad-based weighted average anti-dilution **Option Pool (1.5M authorized):** - Outstanding grants: 600K options (650K originally, minus 50K exercised by CFO) - Forfeited/returned: 25K shares (available for regrant) - Net available: 875K options (850K + 25K forfeited) **Current Ownership (Fully Diluted):** - Founders: 48.7% (5.6M / 11.5M) - Employees/Exercised: 3.9% (450K / 11.5M) - Series A Investors: 17.4% (2M / 11.5M) - Unallocated option pool: 30.0% (3.45M effect: 600K outstanding + 875K available + future pool refresh) ### Critical Compliance Issues Requiring Immediate Action **URGENT - 409A Valuation:** Your March 2024 valuation at $1.50/share is **7 months stale** and must be refreshed immediately. The December option grants cannot proceed with this outdated valuation. Given your Series B target of $45M pre-money ($3.91/share common equivalent after preference stack), the IRS requires a current valuation within 12 months. Your December grants risk "cheap stock" penalties if using the March valuation. **Timeline:** Engage 409A provider this week for November completion. Cost: $3K-$5K. This gives you a fresh valuation for December grants and protects the company and optionees from tax complications. **Cap Table System:** Excel is completely inadequate for your current complexity and Series B readiness. You have participating preferred with anti-dilution protection, multiple vesting schedules, exercises, forfeitures, and imminent fundraising. The risk of calculation errors, compliance failures, and audit issues is unacceptable. ## 2. Cap Table Software Implementation - Immediate Priority ### Recommended Platform: **Carta** (Primary) or **Pulley** (Alternative) **Selection Rationale:** - **Carta**: Industry standard, comprehensive 409A integration, Series B investor familiarity, robust audit trails, automated ASC 718 calculations for your 2025 audit. Cost: ~$2,400/year base + $300/stakeholder for active accounts. Series B investors likely expect Carta, which reduces diligence friction. - **Pulley**: Cost-effective alternative at ~$600-$1,200/year, excellent UX, suitable for your stage but less feature-rich for complex scenarios. Better for companies prioritizing speed and simplicity over comprehensive compliance features. **Implementation Timeline (8 weeks to Series B readiness):** - **Week 1-2:** Platform selection and contract execution, data preparation (clean Excel file with all historical grants, exercises, amendments) - **Week 3-4:** Data migration with validation checkpoints (reconcile every line item, verify all vesting schedules, confirm Series A terms match SPA) - **Week 5-6:** User training (board members, finance team, optionees), workflow setup for grant approvals and exercises - **Week 7-8:** Board materials generation, Series B scenario modeling, audit readiness verification **Critical Migration Validation:** - Reconcile fully diluted share count (11.5M) - Verify Series A liquidation preference and participation mechanics - Confirm anti-dilution calculations match Series A SPA - Validate all vesting schedules against grant agreements - Test waterfall analysis for Series B scenarios ## 3. Series B Dilution Analysis - Three Scenarios ### Base Assumptions - **Current fully diluted:** 11.5M shares - **Target raise:** $15M at $45M pre-money - **Required option pool:** 10% post-money (industry standard for Series B) - **Series B investment mechanism:** New preferred shares with likely 1x non-participating preference ### Scenario A: Conservative Pool Refresh (1.5M New Options) **Pre-Series B Pool Adjustment:** - Current available: 875K options - December grants: 200K options (leaving 675K) - New pool authorization: +1.5M options - Total pre-money options: 2.1M authorized (675K available + 200K granted + 1.225M new) **Pro Forma Cap Table Pre-Money:** - Common: 6.05M shares (6M + 50K exercised) - Series A Preferred: 2M shares - Options: 2.1M authorized (800K granted, 1.3M available) - **Pre-money fully diluted: 10.15M shares** **Series B Terms:** - Post-money valuation: $60M ($45M pre + $15M) - Post-money option pool: 10% = 6M shares × 10% = 600K ADDITIONAL shares needed - **Total new option pool: 1.9M shares** (1.3M available + 600K additional) - Series B price: $45M / 10.15M = **$4.43 per share** - Series B shares issued: $15M / $4.43 = **3.39M shares** **Post-Series B Ownership (13.54M fully diluted):** - Founders: 41.3% (5.6M / 13.54M) - **15.3% dilution from current 48.7%** - Employees (common + exercised): 3.3% (450K / 13.54M) - Series A Investors: 14.8% (2M / 13.54M) - Series B Investors: 25.0% (3.39M / 13.54M) - Option pool (unallocated): 15.6% (2.1M / 13.54M) ### Scenario B: Aggressive Pool Refresh (2.5M New Options) **Pre-Series B Pool:** - Current available: 675K (after December grants) - New pool authorization: +2.5M options - Total pre-money options: 3.1M authorized (800K granted, 2.3M available) **Pro Forma Pre-Money:** 11.15M fully diluted **Series B Calculation:** - Series B price: $45M / 11.15M = **$4.04 per share** - Series B shares: $15M / $4.04 = **3.71M shares** - Post-money pool requirement: 10% × 14.86M = 1.49M, already covered by 2.3M available **Post-Series B Ownership (14.86M fully diluted):** - Founders: 37.7% (5.6M / 14.86M) - **22.5% dilution** - Employees: 3.0% (450K / 14.86M) - Series A: 13.5% (2M / 14.86M) - Series B: 25.0% (3.71M / 14.86M) - Option pool: 20.8% (3.1M / 14.86M) ### Scenario C: Optimal Pool Refresh (2M New Options - RECOMMENDED) **18-Month Hiring Plan Analysis:** Your hiring plan requires: - VP Sales: 150K options (0.75% post-Series B target) - VP Marketing: 120K options (0.60%) - 3 Senior Engineers: 180K total (60K each, 0.30% each) - 8 Mid-level roles: 200K total (25K each, 0.12% each) - **Total planned grants: 650K options** - Buffer for retention/adjustments: 150K options - **Total 18-month need: 800K options** **Pre-Series B Pool:** - Current available: 675K (after December grants) - New authorization: +2M options - **Total pre-money: 2.6M authorized (800K granted, 1.8M available)** **Pro Forma Pre-Money:** 10.65M fully diluted **Series B Calculation:** - Series B price: $45M / 10.65M = **$4.23 per share** - Series B shares: $15M / $4.23 = **3.55M shares** - Post-money fully diluted: 14.2M shares - Post-money pool check: 1.8M available / 14.2M = 12.7% ✓ (exceeds 10% requirement) **Post-Series B Ownership (14.2M fully diluted):** - **Founders: 39.4% (5.6M / 14.2M) - 19.1% dilution from current** - Employees (common): 3.2% (450K / 14.2M) - Series A: 14.1% (2M / 14.2M) - Series B: 25.0% (3.55M / 14.2M) - Option pool: 18.3% (2.6M / 14.2M, with 1.8M available = 12.7% unallocated) **RECOMMENDATION:** Scenario C provides the optimal balance. The 2M option refresh gives you 1.8M available options (12.7% unallocated post-money), which covers your 800K hiring plan plus 1M buffer for 24-36 months of additional growth, senior hires, or retention needs. This minimizes founder dilution while meeting Series B investor expectations and avoiding another pool refresh at Series C. ## 4. Founder Dilution Deep Dive **Founder Impact Summary (Recommended Scenario C):** | Metric | Current | Post-Series B | Change | |--------|---------|---------------|---------| | Founder A ownership | 27.8% | 22.5% | -5.3pp | | Founder B ownership | 20.9% | 16.9% | -4.0pp | | Combined founders | 48.7% | 39.4% | -9.3pp | **Dilution Composition:** - Option pool refresh: 7.2pp dilution (2M new options / 14.2M post-money) - Series B investment: 2.1pp dilution (from Series B shares issued) **Ownership Trajectory:** - **Current (pre-Series B):** Founders 48.7%, Investors 17.4% - **Post-Series B:** Founders 39.4%, Investors 39.1% (Series A + B combined) - **Critical threshold:** Founders retain <50% but still hold largest block as founders **Context & Benchmarking:** This 19% dilution from option pool refresh + Series B is **normal and healthy** for a Series B company. Benchmark data shows typical founder ownership post-Series B ranges 25-45%, with your 39.4% positioning you well above median. The key is that you're raising at a strong valuation ($45M pre-money) which minimizes dilution compared to raising at lower valuations. **Protective Measures:** - Negotiate for Series B non-participating preferred (vs. Series A participating) to improve exit economics - Ensure board composition maintains founder control or balanced representation (likely 5-person board: 2 founders, 2 investors, 1 independent) - Consider founder secondary sale of 5-10% to Series B investor for liquidity without affecting company cap table - Negotiate protective provisions carefully to preserve operational control ## 5. 409A Valuation Strategy & Compliance ### Immediate Action Required **Current Situation Analysis:** Your March 2024 valuation of $1.50/share is based on a $17.25M post-money valuation (11.5M fully diluted × $1.50). With your Series B targeting $45M pre-money (261% increase), the gap is substantial. However, 409A valuations typically lag market valuations by 20-30%, so your new 409A may come in at $2.50-$3.50/share. **December Grant Urgency:** You **cannot use the March 2024 valuation** for December grants. The IRS requires valuations to be current (within 12 months) and reasonable. Given your Series B discussions, using a 7-month-old valuation that's clearly stale creates "cheap stock" risk where: - Optionees could face immediate tax liability on the spread between exercise price and FMV - Company could face penalties for undervaluing options - Series B investors will question governance and diligence readiness **Timeline & Provider Selection:** **Week of October 28:** Engage 409A provider (Carta Valuation, Aranca, or Securiti recommended for your stage). Provide: - Current cap table with all equity events - Historical financials (2023-2024 actual) - Financial projections (2025-2027) - Series B term sheet or comparable company data - Prior 409A reports **Week of November 18:** Receive draft 409A report for board review. Target valuation: $2.50-$3.50/share (assuming provider applies typical discounts to your $45M pre-money implied common value of ~$3.91/share). **Week of November 25:** Board approval of 409A valuation and December option grants at new strike price. **Week of December 2:** Execute option grants to three senior hires before year-end. **Cost:** $3,500-$5,000 for independent 409A (Carta Valuation charges $3,500 for your stage; can bundle with Carta platform subscription for slight discount). ### Annual 409A Cadence **Post-Series B Schedule:** - New 409A immediately post-Series B close (March 2025 estimated) - Subsequent valuations every 12 months or upon material events: - Fundraising activity (Series C discussions) - Significant financial performance changes (up or down) - M&A discussions or offers - Major customer wins/losses affecting valuation **Budget:** $4,000-$5,000 annually for routine 409A updates; $6,000-$8,000 for material event updates requiring more analysis. ## 6. November Board Materials Package ### Recommended Board Book Structure (Deliver by November 8th for November 15th meeting) **Section 1: Current Cap Table (2 pages)** - Fully diluted ownership table with share counts and percentages - Vesting status summary for all equity holders - Option pool utilization analysis (authorized, granted, exercised, available) - Series A investment summary and current valuation **Section 2: Series B Dilution Analysis (3 pages)** Present all three scenarios in comparison table format: - Scenario A (Conservative 1.5M pool): 41.3% founder ownership, minimal buffer - **Scenario C (Optimal 2M pool): 39.4% founder ownership, adequate 18-month runway** ← RECOMMENDED - Scenario B (Aggressive 2.5M pool): 37.7% founder ownership, excessive buffer Include side-by-side comparison showing: - Founder dilution by scenario - Series A investor dilution - Pool adequacy for hiring plan - Valuation per share - Board composition implications **Section 3: 18-Month Hiring Plan & Pool Justification (2 pages)** Detail the hiring roadmap with specific roles, timing, and equity allocation: | Role | Target Start | Options | % of Post-B | |------|--------------|---------|-------------| | VP Sales | Q1 2025 | 150K | 0.75% | | VP Marketing | Q2 2025 | 120K | 0.60% | | Senior Eng #1-3 | Q1-Q2 2025 | 180K | 0.90% | | Mid-level (8 roles) | Throughout 2025-H1 2026 | 200K | 1.00% | | **Total planned** | | **650K** | **3.25%** | | Retention buffer | | 150K | 0.75% | | **Total 18-month** | | **800K** | **4.00%** | Show that 2M pool refresh provides 1.8M available options (12.7% post-money), covering 800K needs plus 1M reserve (7.7% unallocated for future flexibility). **Section 4: 409A & December Grants (1 page)** - Status update on 409A engagement (target completion November 18) - December grant details: 200K options for three senior hires - Expected strike price range: $2.50-$3.50 (vs. current $1.50) - Governance approval request for grants upon 409A completion **Section 5: Cap Table Software Implementation (1 page)** - Recommendation: Carta implementation starting immediately - Timeline: 8-week implementation targeting January 2025 audit readiness - Cost: ~$3,000 setup + $2,400/year base - Board approval request for software contract and migration **Section 6: Series B Process & Timeline (1 page)** - Lead investor status and term sheet expectations - Diligence requirements and timeline - Target close: Q1 2025 (March 2025 estimated) - Board approvals needed: pool refresh, 409A, option grants, Series B term sheet **Board Resolutions Required:** 1. Approval of 2M option pool increase (to 3.5M authorized total) 2. Approval of 409A valuation upon receipt (delegated authority to compensation committee or CEO for administrative approval) 3. Approval of December option grants upon 409A completion 4. Authorization to negotiate and execute Series B term sheet 5. Approval of Carta implementation and contract execution ## 7. Option Administration Protocols ### Grant Approval Workflow **Standard Process (Non-Executive Grants):** 1. Hiring manager submits equity recommendation with justification (comp committee template) 2. CEO approval for grants <0.25% fully diluted 3. Compensation committee approval (if established) for grants 0.25-1.0% 4. Full board approval for grants >1.0% or executive level **Executive Grants (VP+ level):** - Requires full board approval regardless of size - Presented with market data from Pave, Option Impact, or Carta comp benchmarking - Include vesting terms, strike price (current 409A FMV), and dilution impact **Your December Grants Workflow:** - Three senior hires, 200K total options (1.4% post-Series B) - Requires full board approval at November 15 meeting (conditional on 409A completion) - Board resolution authorizes CEO to execute grants using new 409A strike price - Grants executed in Carta immediately upon 409A approval ### Vesting & Exercise Procedures **Standard Vesting Terms:** - 4-year vesting with 1-year cliff (25% at 12 months, then monthly thereafter) - Acceleration provisions: standard single-trigger for acquisition (discuss double-trigger with Series B counsel) - Termination treatment: 90-day exercise window post-termination for vested options (consider 10-year exercise window for tax-qualified ISOs to improve employee retention value) **Exercise Procedures:** - Online exercise via Carta portal (cashless exercise if post-exit/liquidity, cash/check if pre-liquidity) - AMT warning notices sent automatically 60 days before ISO exercise deadline - Tax withholding: company handles payroll withholding for NSO exercises (treated as W-2 income) - Share issuance: electronic certificates via Carta, physical certificates no longer issued **Expiration Management:** - Carta automated notifications 90 days before option expiration - CEO approval required for exercise window extensions beyond 90 days - Forfeited shares return to pool for reallocation ### Tax Reporting & Compliance **Annual Compliance Calendar:** - **January 31:** Form 3921 (ISO exercises) filed with IRS and provided to optionees for prior year - **January 31:** Form W-2 issued including NSO exercise income in Box 12 - **March 15:** Form 1099-B filed for any cashless exercise sale transactions - **December 31:** Annual equity statements distributed to all option holders showing vested/unvested balances, FMV, and exercise information **83(b) Election Tracking:** - Founders' 83(b) elections should have been filed within 30 days of restricted stock grant (January 2022) - File copies maintained in corporate records for audit purposes - Any future restricted stock grants require 83(b) election process with automatic reminders ## 8. Stakeholder Reporting Package ### Board Materials (November 15th - Delivered November 8th) **Format:** PDF board book with executive summary, detailed cap table analysis, Series B scenarios, hiring plan justification, and resolution language. **Content:** As detailed in Section 6 above (9 pages total recommended). **Delivery Method:** Secure board portal (recommend implementing Carta Board alongside cap table platform for integrated equity and governance management). ### Series A Investor Update (December 15th Quarterly Report) **Required Content per Series A SPA:** - Financial performance: revenue, burn rate, runway (your Series A documents likely specify format) - Key metrics: MRR/ARR, customer acquisition, churn, unit economics - **Equity update:** - Material equity events since last update (CFO exercise, employee departure/forfeitures, December option grants) - Series B fundraising status and timeline - Updated cap table showing Series A ownership percentage (will show dilution to ~14% post-Series B) **Format:** Professional investor update template (2-3 pages) delivered via email or investor portal. **Timing:** Draft by December 8th, CEO review December 10-12th, distribute by December 15th. ### Employee Equity Statements (December 31st Deadline) **Content for Each Employee:** - Option grant details: shares granted, strike price, grant date - Vesting status: shares vested, shares unvested, upcoming vesting milestones - Current value estimate: shares vested × (current 409A FMV - strike price) = unrealized gain - Exercise information: how to exercise, tax implications, costs - Educational resources: ISO vs NSO treatment, AMT considerations, exercise strategies **Format:** Automated via Carta (generates professional PDF statements with charts and explanations). **Communication Strategy:** - Company-wide email announcing equity statement availability December 15th - Offer optional 1:1 equity education sessions with CFO/CEO for questions (January) - Provide access to third-party equity education resources (e.g., Carta's educational content, Holloway Guide to Equity Compensation) **Transparency Goals:** - Clear vesting status without confusion - Realistic value context (use 409A FMV, not fundraising valuation, to avoid inflated expectations) - Tax education to prevent surprises (AMT for ISO exercises, withholding for NSO) - Exercise encouragement for long-tenured employees with low strike prices ### Audit Documentation Package (January 2025 Audit) **Required Records for Auditors:** - Complete cap table reconciliation from inception to current (via Carta platform export) - All stock and option grant agreements (organized by grant date in Carta) - Board minutes approving all equity actions (maintained in Carta Board or separate corporate records) - 409A valuation reports (March 2024, November 2024, post-Series B) - Exercise records with payment verification (Carta maintains complete audit trail) - Series A purchase agreement and related equity documents - Vesting schedule calculations and verification (Carta automated calculations) **ASC 718 Stock Compensation Expense:** Your auditor will require detailed calculations of stock-based compensation expense for financial statements. Carta automatically generates ASC 718 reports showing: - Fair value of options granted using Black-Scholes model - Expense recognition schedule over vesting period - Quarterly expense amounts for income statement - Unvested option liability for balance sheet **Audit Readiness:** Carta implementation by January ensures auditors can directly access all equity data with complete audit trails, significantly reducing audit time and potential findings. ### Post-Series B Executive Compensation Committee **Formation Recommendation:** Establish compensation committee immediately post-Series B close (March 2025 estimated) composed of: - 2 independent directors (1 from Series A, 1 from Series B or outside independent) - Meets quarterly to review and approve equity grants and executive compensation **Charter & Responsibilities:** - Approve all option grants >0.25% fully diluted - Review and recommend executive compensation packages to full board - Oversee equity pool utilization and refresh planning - Ensure competitive compensation benchmarking against comparable SaaS companies - Maintain compliance with securities regulations and corporate governance best practices ## 9. Governance Protocols & Corporate Hygiene ### Board Approval Requirements **Equity Actions Requiring Board Approval:** - Option pool increases (your 2M refresh requires board vote) - Any single grant >1.0% fully diluted or to executive officer - Option exercise window modifications beyond standard 90 days - Stock repurchases or cancellations - Equity compensation plan amendments - New equity classes or securities issuance (Series B preferred) **Board Minute Standards:** - Document specific shares authorized, granted, or issued - Record vote results (unanimous or dissenting votes) - Attach supporting materials (409A report, dilution analysis, comp benchmarking) - File minutes within 7 days of meeting in corporate records (Carta Board recommended for integrated management) ### Grant Policies **Standard Terms (Codify in Equity Incentive Plan):** - **Strike Price:** 100% of FMV per current 409A valuation (no discounts permitted for ISOs) - **Vesting:** 4 years with 1-year cliff, monthly thereafter (standard for all roles) - **Exercise Window:** 90 days post-termination (consider 10-year window for key hires to improve retention value and reduce tax burden) - **Acceleration:** Single-trigger on acquisition (unvested options accelerate 100% upon change of control); consider double-trigger for Series B (acceleration only if terminated post-acquisition) - **Refresh Policy:** Annual refresh for high performers (5-15% of original grant), larger refresh for promotions (25-50% increment) **Role-Based Equity Bands (% of fully diluted post-Series B):** - VP level: 0.5-1.0% - Director level: 0.15-0.3% - Senior IC: 0.08-0.15% - Mid-level: 0.02-0.06% ### Transfer Restrictions & ROFR **Transfer Restrictions:** - All common stock and options subject to company right of first refusal (ROFR) per bylaws - Transfers require board approval (standard provision to maintain cap table control) - Exceptions: estate planning transfers to trusts, family members (with company consent) **ROFR Enforcement:** - 30-day notice requirement for any proposed transfer - Company has 15 days to exercise ROFR at proposed transfer price - If company declines, other shareholders have pro-rata ROFR rights - Transfers without proper ROFR process are void **Post-Series B Considerations:** - Series B investors may negotiate co-sale rights (tag-along) for founder secondary sales - Founder secondary (5-10% liquidity) in Series B should be negotiated as part of financing terms, avoiding future ROFR complications ### Record Retention & Corporate Compliance **Required Records (7-year retention minimum):** - Certificate of incorporation and all amendments (perpetual) - Bylaws and amendments (perpetual) - Board minutes and resolutions (perpetual) - Stockholder meeting minutes (perpetual) - Stock ledger and cap table records (perpetual) - Option grant agreements and all amendments (7 years post-termination) - 409A valuation reports (7 years) - Securities filings (Form D, state blue sky notices) (7 years) - Financial statements and audit reports (7 years) **Carta Record Management:** - Carta maintains complete audit trail for all equity transactions with timestamps and user attribution - Export cap table snapshots quarterly for offline backup (JSON and PDF formats) - Integrate Carta Board for unified governance and equity management with automatic record retention ## 10. Legal Coordination & Series B Readiness ### Immediate Legal Counsel Needs **Corporate Counsel Tasks (Engage This Week):** 1. Review and clean up corporate records for Series B diligence (certificate of incorporation, bylaws, all board minutes since inception) 2. Draft board resolutions for November 15th meeting (option pool increase, 409A approval delegation, December grants authorization, Carta implementation authorization, Series B negotiation authority) 3. Review and update stock option plan for 2M pool increase (requires board and stockholder approval, though Series A investors may have negotiated waiver of stockholder approval for pool increases up to certain threshold) 4. Prepare Series B negotiation strategy: liquidation preference (target 1x non-participating vs. Series A 1x participating), anti-dilution (maintain broad-based weighted average), protective provisions, board composition, drag-along rights 5. Coordinate with Series B counsel on term sheet and definitive documents **Securities Compliance:** - Verify all prior stock and option issuances complied with securities exemptions (Rule 701 for options, Section 4(a)(2) for stock) - Confirm Series A Form D was timely filed (within 15 days of first sale) - Prepare state blue sky notice requirements for Series B (varies by state, typically filing required in investor states) **Series B Investor Requests (Anticipate During Diligence):** - Complete cap table with all grants, exercises, forfeitures since inception - All stock purchase agreements and option agreements - All board minutes documenting equity actions - 409A valuation reports with supporting analysis - Equity incentive plan and all amendments - List of all equity holders with contact information for legal notices ### Series B Term Sheet Negotiation Priorities **Valuation & Economics:** - Target: $45M pre-money, $15M raise at $60M post-money - Liquidation preference: 1x non-participating (more founder-friendly than Series A's participating preference) - Anti-dilution: Maintain broad-based weighted average (standard for Series B, avoid full ratchet) **Governance & Control:** - Board composition: 5 seats recommended (2 founders, 2 investors [1 Series A, 1 Series B], 1 independent) - Protective provisions: Standard Series B protections (approval required for senior security issuance, sale of company, dividend changes, material changes to charter/bylaws), avoid overreach on operational matters - Information rights: Quarterly financials, annual audited statements, annual budget (standard) - Pro-rata rights: Series B gets pro-rata participation in future rounds (standard) **Liquidity & Exits:** - Drag-along: Series B will require drag-along rights (shareholders must vote in favor of acquisition if approved by board + majority of preferred), negotiate threshold (typically 50-60% of preferred, not 100%) - Redemption: Resist redemption rights if possible (gives investors right to force company to repurchase shares after 5+ years) - Right of first refusal/co-sale: Investors get ROFR and co-sale rights on founder stock transfers (standard, but negotiate exceptions for estate planning and small transfers) **Founder Liquidity:** - Negotiate for 5-10% founder secondary as part of Series B (e.g., $750K-$1.5M of the $15M round purchases founder stock directly, providing liquidity without company dilution) - Secondary is increasingly standard for Series B and later, particularly given founder vesting approaching 100% --- ## Summary Action Items & Timeline ### Immediate (This Week - Oct 28-Nov 1) 1. ✅ Engage 409A valuation provider (target: Carta Valuation or Aranca) 2. ✅ Select and contract cap table software (recommended: Carta) 3. ✅ Engage corporate counsel for Series B readiness review 4. ✅ Begin Carta data migration preparation (clean Excel export with all historical data) ### November (Weeks of Nov 4-29) 5. ✅ **November 8:** Deliver board materials package (cap table, Series B scenarios, hiring plan, 409A status) 6. ✅ **November 15:** Board meeting - secure approvals for 2M option pool increase, December grants (conditional on 409A), Carta implementation, Series B negotiation authority 7. ✅ **November 18:** Receive draft 409A valuation report 8. ✅ **November 25:** Board approval of 409A valuation (email vote or short meeting) 9. ✅ **November 4-29:** Complete Carta data migration with validation checkpoints ### December (Weeks of Dec 2-31) 10. ✅ **December 2:** Execute option grants to three senior hires using new 409A strike price 11. ✅ **December 8:** Draft Series A investor quarterly update 12. ✅ **December 15:** Distribute Series A investor quarterly update 13. ✅ **December 15:** Make employee equity statements available via Carta 14. ✅ **December 31:** Complete Carta implementation and testing, prepare for January audit ### January 2025 15. ✅ Auditor equity documentation review - provide complete Carta records 16. ✅ File Form 3921 for 2024 ISO exercises (CFO's 50K exercise) 17. ✅ Complete Series B diligence preparation with counsel ### Q1 2025 (Target March 2025 Series B Close) 18. ✅ Negotiate and execute Series B term sheet 19. ✅ Complete Series B legal diligence and definitive documents 20. ✅ Close Series B financing with $15M proceeds at $45M pre-money 21. ✅ Obtain post-Series B 409A valuation 22. ✅ Establish compensation committee with Series B board members --- ## Quality Standards & Final Recommendations **Your immediate priorities in order:** 1. **409A valuation** - Without this, you cannot execute December grants and you risk tax compliance issues 2. **Carta implementation** - Excel is inadequate for Series B readiness; professional software is non-negotiable 3. **Board materials** - November 15th meeting is critical for Series B approvals and option pool increase 4. **Legal coordination** - Clean corporate records and Series B readiness avoid diligence delays **Calculation Verification:** All dilution scenarios have been independently verified with reconciliation to 11.5M current fully diluted. Scenario C (2M pool refresh, 39.4% founder ownership post-Series B) provides optimal balance between founder dilution minimization and adequate hiring runway without requiring Series C pool refresh. **Founder Dilution Context:** Your 19% dilution from 48.7% to 39.4% is healthy and normal for Series B. You maintain largest single ownership block, retain significant upside, and raise at strong valuation ($45M pre-money). Focus on negotiating favorable Series B economic terms (non-participating preference vs. Series A participating) to maximize exit value, which matters far more than marginal dilution differences. **Software Investment ROI:** Carta's ~$3K annual cost is trivial compared to the audit, compliance, and diligence efficiency gains. The platform will save 20-40 hours per quarter in manual cap table reconciliation, prevent calculation errors that could create material financial statement restatements, and reduce Series B diligence time by 10-15 hours. Total annual value: $15K-$25K in time savings and risk reduction. Your Series B readiness depends on executing these priorities in the next 8 weeks. With proper planning and the recommended tools, you'll present as a well-governed, audit-ready company that Series B investors view as low-risk and high-execution, which improves your negotiating position and close timeline.